



VENTRIPOINT INSTALLS FIRST VMS™ 3D HEART ANALYSIS SYSTEM IN UNITED STATES AT CHILDREN'S HOSPITAL & MEDICAL CENTER, OMAHA

***** Will Serve as Primary Investigator for Multi-Center Validation Study for Next Database in Congenital Heart Disease *****

Seattle, Washington, January 10, 2011 – As part of VentriPoint Diagnostics' (TSXV:VPT) rollout strategy, it is announcing the first VMS™ research site for right heart analysis in the United States at the University of Nebraska Medical Center/Creighton University Joint Division of Pediatric Cardiology at Children's Hospital & Medical Center in Omaha.

"We are pleased to be the first site in the US to be working with a research version of the VentriPoint Medical System (VMS)", said Dr. Shelby Kutty, Assistant Professor of Pediatrics and Radiology at the University of Nebraska Medical Center. "As the primary investigator of a multi-center trial to validate the systemic right ventricle database, I am enthusiastic about the advantages and accuracy of the VMS for patients with congenital heart disease. I expect that the VMS will change the way pediatric and adult cardiologists monitor right ventricular dimensions and function in our patients with systemic right ventricles."

This first US-based research project will study adult and pediatric patients with systemic right ventricle who have undergone surgical repair and are at risk for right heart failure at different ages. Both MRI and VMS™ 3D technology will be utilized for same day analysis.

This will allow a direct comparison between these different technologies and further demonstrate the ability of 2D ultrasound enhanced with VMS™ 3D technology to produce results that are comparable to MRI. The time to provide the medical professionals with an analysis will also be recorded to validate this additional benefit of using VMS™ over MRI. It is anticipated the study will take four months and be presented at a major cardiology conference later this year.

"We continue on our plan to expand our VMS™ device for additional congenital heart diseases such as systemic right ventricle which is a form of blue baby syndrome where the major blood vessels from the heart are reversed," said Dr. George Adams, CEO of VentriPoint. "The incidence of systemic right ventricle disease is a major fraction of congenital heart disease cases."

As part of a controlled deployment plan, the Company has successfully installed its VMS™ platforms in Canada at The Hospital for Sick Children in Toronto and in Europe at the Rikshospitalet University Hospital in Oslo, Norway. Additional installations are in process and will be announced as each system becomes operational. VentriPoint plans to have ten systems installed and operational in the US, Europe and Canada by the end of the second calendar quarter.

About Children's Hospital & Medical Center, Omaha

Children's Hospital & Medical Center is the only full-service, pediatric health care center in Nebraska. It provides expertise in more than 30 pediatric specialty services to children and

families across a five-state region and beyond, and provides care to more than 250,000 children each year. The 145-bed, non-profit hospital houses the only dedicated pediatric emergency department in the region. A pediatric affiliation established between Children's and the University of Nebraska Medical Center College of Medicine supports enhancements in pediatric education, research and clinical care. For more information, visit www.ChildrensOmaha.org.

About VentriPoint Diagnostics Ltd.

VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease in children is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure - a multibillion dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of VentriPoint's VMS™ diagnostic tool and it is pursuing the US-FDA approval through the 510(k) process.

For further information, please contact:

VentriPoint Diagnostics Ltd.

Dr. George Adams, CEO
Telephone: (206) 283-0221, ext. 401
email: gadams@ventripoint.com

Howard Group Inc.

Peter Weichler/David Burwell
Telephone: 1.888-221-0915 or 403-221-0915
email: Peter@howardgroupinc.com
Dave@howardgroupinc.com

Cautionary Note Regarding Forward-Looking Statements: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

